Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

• DOI: 10.1038/s41375-018-0023-2
• Publication Date: 2018-02-02T10:21:38Z
• Authors: S Rule; W Jurczak; M Jerkeman; C Rusconi; M Trneny; F Offner; D Caballero; C Joao; M Witzens-Harig; G Hess; I Bence-Bruckler; S-G Cho; C Thieblemont; W Zhou; T Henninger; J Goldberg; J Vermeulen; M Dreyling
• Keywords: Temsirolimus; Open label